CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Wednesday, January 18th at 10:00 AM ET
HOUSTON, January 5, 2023 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the Virtual Investor 2023 Companies to Watch Event on Wednesday, January 18, 2023 at 10:00 AM ET.
A live video webcast of the presentation will be available on the Events page of the Investors section of the Company's website (cnspharma.com). A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cns-pharmaceuticals-to-present-at-the-virtual-investor-2023-companies-to-watch-event-301714427.html
SOURCE CNS Pharmaceuticals, Inc.
Released January 5, 2023